Delivering the next generation gene therapies

Our mission

Gene Therapy based on Adeno-Associated Viral (AAV) vectors has proven to be transformative in the treatment of genetic illnesses, however, the small vector payload limits their further application. The AAVantgarde cutting-edge gene therapy technology platforms are focused on solving the constraint of oversized gene delivery, with our technologies opening up the opportunity for genetic medicine delivery to more underserved patients with debilitating diseases.

About us

AAVantgarde is a clinical stage, Italian headquartered, international biotechnology company.
It is validating its two proprietary AAV platforms in the clinic in two inherited retinal diseases with the potential that its technology could extend into many disease areas.